Carcinoma, HepatocellularNCT06156748
CT Imaging for Guiding PA-TACE for HCC
An observational study of Carcinoma, Hepatocellular, run by Zhujiang Hospital at 1 site in China.
Trial summary
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Carcinoma, Hepatocellular
- What is being tested?
- postoperative adjuvant transarterial chemoembolization
- Type of treatment
- Surgery or procedure
- How many people
- 1,770 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2019to 30 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study included 1,488 patients (median age, 52 years [IQR, 45-61 years]; 1,309 male).
Who may be able to join
- CT scans acquired no more than one month before surgery
- Confirmation of HCC diagnosis by pathological examination
- Curative surgical resection
Who cannot join
- Prior antitumor treatment
- Macrovascular thrombosis or metastasis
- Perioperative mortality
- Unqualified image artifacts
- Tumor rupture
- MVI status not reported
Trial locations and contacts
1 site in 1 country.
China1 site
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280
About this study
Official title: CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.
- Conditions
- Carcinoma, Hepatocellular
- Being tested
- postoperative adjuvant transarterial chemoembolization
- Keywords
- Carcinoma, Hepatocellular
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
postoperative adjuvant transarterial chemoembolizationProcedure or surgery
HCC patients received hepatectomy and PA-TACE.
| Study group | Role | What they receive |
|---|---|---|
| Hepatectomy alone | Not described Receives: Procedure: postoperative adjuvant transarterial chemoembolization | |
| PA-TACE | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.
Measured: the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2023
- Study start1 Oct 2019
- Primary completion30 Jun 2025
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Carcinoma, HepatocellularStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,770 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zhujiang Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Quan Xianyue, Zhujiang Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06156748
- Sponsor's protocol ID
- 2019-KY-021-01
- Status last verified
- Nov 2023
- First submitted
- 23 Nov 2023
- Last updated
- 28 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Li X, Liang X, Li Z, Liang J, Qi Z, Zhong L, Geng Z, Liang W, Quan X, Liang C, Liu Z. A novel stratification scheme combined with internal arteries in CT imaging for guiding postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study. Int J Surg. 2024 May 1;110(5):2556-2567. doi: 10.1097/JS9.0000000000001191.
PubMed 38377071
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma
- ClinicalTrials.gov ID
- NCT06156748
- Acronym / sponsor ID
- 2019-KY-021-01
- Conditions
- Carcinoma, Hepatocellular
- Keywords
- Carcinoma, Hepatocellular
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,770 participants (actual)
- Lead sponsor
- Zhujiang HospitalUniversity, hospital or other
- Study start
- 1 Oct 2019 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 5 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hepatectomy alone | – | Procedure: postoperative adjuvant transarterial chemoembolization |
| PA-TACE | – | – |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study included 1,488 patients (median age, 52 years [IQR, 45-61 years]; 1,309 male).
Key inclusion criteria (3 listed)
- CT scans acquired no more than one month before surgery
- Confirmation of HCC diagnosis by pathological examination
- Curative surgical resection
Key exclusion criteria (6 listed)
- Prior antitumor treatment
- Macrovascular thrombosis or metastasis
- Perioperative mortality
- Unqualified image artifacts
- Tumor rupture
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| postoperative adjuvant transarterial chemoembolizationHCC patients received hepatectomy and PA-TACE. | Procedure or surgery | Hepatectomy alone |
Primary outcome
Overall survival
Time frame: the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.
Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2025.
- Derived from this study: PubMed 38377071Li X, Liang X, Li Z, Liang J, Qi Z, Zhong L, Geng Z, Liang W, Quan X, Liang C, Liu Z. A novel stratification scheme combined with internal arteries in CT imaging for guiding postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study. Int J Surg. 2024 May 1;110(5):2556-2567. doi: 10.1097/JS9.0000000000001191.
- Individual participant dataSharing planned: No
Related trials for Carcinoma, Hepatocellular
RecruitingPhase 2/3
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
HCC
Not yet recruitingObservational study
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
Hepatocellular Carcinoma (HCC)
Active, not recruitingPhase 2
TheraSphere With Durvalumab and Tremelimumab for HCC
Hepatocellular Carcinoma
RecruitingPhase 1
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
RecruitingPhase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Carcinoma, Hepatocellular, run by Zhujiang Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06156748, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2025.